Vaxxinova
Innovating strategies for Animal Health in the Netherlands.
With strong investments in R&D, the international biotech company Vaxxinova is an innovative member of the Agri/food and Life Sciences & Health sectors in the Netherlands.
Since 2016, Vaxxinova’s location in the Netherlands also serves as the headquarters for the global Vaxxinova Group.
Although Vaxxinova was officially named and founded in 2010, the company’s predecessors have been in the livestock vaccine and diagnostics business since the 1950s. Vaxxinova has more than six decades of expertise in disease prevention for production animals and its products and services are available in more than 75 countries.
Global headquarters in the Netherlands
Vaxxinova’s current technology network comprises production, research & development and diagnostic facilities in 10 countries. Besides the Netherlands, Vaxxinova has operations in Brazil, Chile, Italy, Germany, Japan, Jordan, Norway, Thailand, and the USA.
The choice for Nijmegen and the East of Netherlands was obvious. Some of our collaboration partners are nearby. We have access to talent and expertise at the universities of Münster, Utrecht and Wageningen. The major airports are easily accessible by train and car.
Research & development hub for collaboration
Besides as a headquarter, where the management and support functions of Vaxxinova hold office, Nijmegen is also the seat of the European R&D and Regulatory Affairs team.
In modern lab facilities a dedicated team of researchers works on innovative solutions for disease prevention in poultry and livestock. The regulatory team prepares the dossiers to guide these solutions to market. Both groups are part of the larger R&D and regulatory network.
Recent Developments
A milestone was reached in November 2024, when Vaxxinova received EU marketing approval for Vaxxon® ND Clone, its first poultry vaccine with a EU wide registration. This marks the introduction of a broader EU licensed poultry vaccine portfolio in the next years.
Where the Netherlands serve as R&D hub for the EU market, production facilities and sales management continue to be based in Italy.
Access to talent and expertise in the Netherlands
Vaxxinova states: “The choice for Nijmegen and the East of Netherlands was obvious. Some of our collaboration partners are nearby. We have access to talent and expertise at the universities of Münster, Utrecht and Wageningen. The major airports are easily accessible by train and car.”
Excellent quality of life in the Netherlands
Vaxxinova further explains: “The quality of life in the East Netherlands is excellent, offering a safe living environment, excellent education and good housing at reasonable prices. Oost NL (East Netherlands Development Agency), together with the Netherlands Foreign Investment Agency (NFIA) supported our establishment and expansions through introductions to their network”.
The Netherlands leads in One Health
The Netherlands has been a leader in integrating environment and human and animal health under the One Health programme. The country’s high concentration of livestock makes it an ideal testing ground for One Health – and a frontrunner in identifying and developing solutions for emerging infectious diseases. With companies such as Vaxxinova in the life sciences and health ecosystem, the Netherlands strives to continue being a leader in this area.
